Jade Biosciences, Inc. (JBIO) Stock Forecast
JBIO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 10 analysts
- Price target
- $50.12 average of analyst targets
- Upside to target
- +272.1% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.73
- 52-week range
- $8.95 – $26.85
JBIO analyst ratings
10 analystsNumber of analysts at each rating.
JBIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
JBIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.79 | −$0.79 | −$0.79 | — | — | 1 |
| Current fiscal year (2026) | −$2.93 | −$2.93 | −$2.93 | −$3.19 | +17.3% | 1 |
| Next fiscal year (2027) | −$2.66 | −$2.66 | −$2.66 | −$2.93 | +9.2% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
JBIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
JBIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
JBIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | −$0.57 | −$0.57 | −$0.79 | — | 0 up · 1 down |
| Current fiscal year (2026) | $0.00 | $0.00 | −$2.28 | −$2.28 | −$2.93 | — | 0 up · 1 down |
| Next fiscal year (2027) | $0.00 | $0.00 | −$2.28 | −$2.28 | −$2.66 | — | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
JBIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; JBIO beat in 1 of 12.
What analysts expect from JBIO
10 analysts cover Jade Biosciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $50.12, 272.1% above the latest close of $13.47. Analysts expect earnings of −$2.93 per share for 2026, +17.3% from a year earlier. For 2027 the average estimate is −$2.66 per share. Jade Biosciences beat the EPS estimate in 1 of the last 12 quarters.
Related: JBIO income statement, JBIO key metrics, JBIO chart. See the JBIO stock overview for the latest quote and news.
JBIO forecast FAQ
What is Jade Biosciences's price target?
The average analyst price target for Jade Biosciences is $50.12, 272.1% above the latest close of $13.47.
Is Jade Biosciences a buy, hold or sell?
Of 10 analysts covering Jade Biosciences, 10 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Jade Biosciences's EPS forecast?
Analysts forecast −$2.93 per share for 2026 (range −$2.93 to −$2.93); for 2027 the estimate is −$2.66.
When does Jade Biosciences report earnings?
Jade Biosciences is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.73.
Does Jade Biosciences usually beat earnings estimates?
Jade Biosciences reported EPS at or above the analyst estimate in 1 of the last 12 quarters.